99 related articles for article (PubMed ID: 7712466)
1. Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux.
Brouty-Boyé D; Kolonias D; Wu CJ; Savaraj N; Lampidis TJ
Cancer Res; 1995 Apr; 55(8):1633-8. PubMed ID: 7712466
[TBL] [Abstract][Full Text] [Related]
2. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
3. Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells.
Kang DI; Kang HK; Gwak HS; Han HK; Lim SJ
Drug Deliv; 2009 Jul; 16(5):261-7. PubMed ID: 19538007
[TBL] [Abstract][Full Text] [Related]
4. Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
Zhou J; Cheng SC; Luo D; Xie Y
Biochem Biophys Res Commun; 2001 Feb; 280(5):1237-42. PubMed ID: 11162660
[TBL] [Abstract][Full Text] [Related]
5. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.
Alvarez M; Paull K; Monks A; Hose C; Lee JS; Weinstein J; Grever M; Bates S; Fojo T
J Clin Invest; 1995 May; 95(5):2205-14. PubMed ID: 7738186
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.
Yu D; Liu B; Tan M; Li J; Wang SS; Hung MC
Oncogene; 1996 Sep; 13(6):1359-65. PubMed ID: 8808711
[TBL] [Abstract][Full Text] [Related]
7. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
8. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
9. Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line.
Duensing S; Brevis Nunez F; Meyer N; Anastassiou G; Nasarek A; Grosse J; Buer J; Probst M; Ganser A; Alzpodien J
Invasion Metastasis; 1996; 16(2):65-72. PubMed ID: 9030241
[TBL] [Abstract][Full Text] [Related]
10. Effects of vinblastine, colchicine, and verapamil on rhodamine 123 accumulation in human P-glycoprotein-positive leukemia cells.
Lautier D; Canitrot Y; Salmon JM
Anticancer Res; 1994; 14(6B):2589-95. PubMed ID: 7872686
[TBL] [Abstract][Full Text] [Related]
11. Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line.
Le Moyec L; Tatoud R; Degeorges A; Calabresse C; Bauza G; Eugène M; Calvo F
Cancer Res; 1996 Aug; 56(15):3461-7. PubMed ID: 8758912
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
13. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
[TBL] [Abstract][Full Text] [Related]
14. Reduced drug resistance in a multidrug resistant cell line by 5,8,11,14-eicosatetraynoic acid.
Anderson KM; Harris JE
Res Commun Mol Pathol Pharmacol; 1994 Nov; 86(2):195-203. PubMed ID: 7881868
[TBL] [Abstract][Full Text] [Related]
15. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
16. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
[TBL] [Abstract][Full Text] [Related]
17. Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells.
Limtrakul P; Siwanon S; Yodkeeree S; Duangrat C
Phytomedicine; 2007 Jun; 14(6):381-9. PubMed ID: 17467965
[TBL] [Abstract][Full Text] [Related]
18. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
19. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells.
Gao P; Zhou GY; Lei DP; Zhang XF; Li L; Xu JW; Lin XY
Cytotherapy; 2007; 9(8):795-801. PubMed ID: 17917879
[TBL] [Abstract][Full Text] [Related]
20. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
Lee JS; Paull K; Alvarez M; Hose C; Monks A; Grever M; Fojo AT; Bates SE
Mol Pharmacol; 1994 Oct; 46(4):627-38. PubMed ID: 7969041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]